{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:14:41Z","timestamp":1793420081087,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bbrc.2024.151215","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:28:12Z","timestamp":1734568092000},"page":"151215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics"],"prefix":"10.1016","volume":"745","author":[{"given":"Yanwei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huashan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixue","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2024.151215_bib1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics: Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2024.151215_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9235638","article-title":"Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions","volume":"2020","author":"Ralli","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.bbrc.2024.151215_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","article-title":"Targeted therapy and immunotherapy in melanoma","volume":"41","author":"Lazaroff","year":"2023","journal-title":"Dermatol. Clin."},{"issue":"50","key":"10.1016\/j.bbrc.2024.151215_bib4","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1016\/j.vaccine.2021.08.026","article-title":"A bcg success story: from prevention of tuberculosis to optimal bladder cancer treatment","volume":"39","author":"Lamm","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.bbrc.2024.151215_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"Bcg immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann. Surg."},{"issue":"11","key":"10.1016\/j.bbrc.2024.151215_bib6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1524-4725.1993.tb00989.x","article-title":"Pooled analysis of the efficacy of bacille calmette-guerin (bcg) immunotherapy in malignant melanoma","volume":"19","author":"Tan","year":"1993","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"10.1016\/j.bbrc.2024.151215_bib7","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/181987","article-title":"Bladder cancer immunotherapy: bcg and beyond","volume":"2012","author":"Askeland","year":"2012","journal-title":"Adv. Urol."},{"issue":"7","key":"10.1016\/j.bbrc.2024.151215_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002707","article-title":"Novel personalized cancer vaccine platform based on bacillus calmette-gu\u00e8rin","volume":"9","author":"Yl\u00f6sm\u00e4ki","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"13","key":"10.1016\/j.bbrc.2024.151215_bib9","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann. Surg Oncol."},{"issue":"7","key":"10.1016\/j.bbrc.2024.151215_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004325","article-title":"Novel intravesical bacterial immunotherapy induces rejection of bcg-unresponsive established bladder tumors","volume":"10","author":"Moreo","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbrc.2024.151215_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003939","article-title":"Fimh confers mannose-targeting ability to bacillus calmette-guerin for improved immunotherapy in bladder cancer","volume":"10","author":"Zhang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"38","key":"10.1016\/j.bbrc.2024.151215_bib12","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1016\/j.biomaterials.2013.09.027","article-title":"A magnetic chitosan hydrogel for sustained and prolonged delivery of bacillus calmette-gu\u00e9rin in the treatment of bladder cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"issue":"19","key":"10.1016\/j.bbrc.2024.151215_bib13","doi-asserted-by":"crossref","first-page":"7903","DOI":"10.1007\/s00253-019-10057-0","article-title":"Mycobacterium bovis bcg in metastatic melanoma therapy","volume":"103","author":"Benitez","year":"2019","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"5","key":"10.1016\/j.bbrc.2024.151215_bib14","article-title":"A case of systemic toxicity related to intravesical bacillus calmette-guerin for the treatment of bladder cancer","volume":"13","author":"Gupta","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.bbrc.2024.151215_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.actbio.2021.04.009","article-title":"Peg-based thermosensitive and biodegradable hydrogels","volume":"128","author":"Shi","year":"2021","journal-title":"Acta Biomater."},{"issue":"13","key":"10.1016\/j.bbrc.2024.151215_bib16","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1039\/D0TB02877K","article-title":"Recent advances in thermo-sensitive hydrogels for drug delivery","volume":"9","author":"Yu","year":"2021","journal-title":"J. Mater. Chem. B"},{"issue":"6","key":"10.1016\/j.bbrc.2024.151215_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/joim.13037","article-title":"Clinical and molecular insights into bcg immunotherapy for melanoma","volume":"288","author":"Kremenovic","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bbrc.2024.151215_bib18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fimmu.2017.00965","article-title":"Mycobacterium bovis bacillus calmette-gu\u00e9rin alters melanoma microenvironment favoring antitumor t cell responses and improving m2 macrophage function","volume":"8","author":"Lardone","year":"2017","journal-title":"Front. Immunol."},{"issue":"31","key":"10.1016\/j.bbrc.2024.151215_bib19","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces cd4-dependent tumor-specific immunity through tumor-intrinsic interferon-\u03b3 signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.bbrc.2024.151215_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4161\/hv.26568","article-title":"Allogeneic tumor cell vaccines: the promise and limitations in clinical trials","volume":"10","author":"Srivatsan","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"issue":"1","key":"10.1016\/j.bbrc.2024.151215_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2012.06.015","article-title":"Coencapsulation of tumor lysate and cpg-odn in plga-microspheres enables successful immunotherapy of prostate carcinoma in tramp mice","volume":"162","author":"Mueller","year":"2012","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.bbrc.2024.151215_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201800837","article-title":"Tumor lysate-loaded lipid hybrid nanovaccine collaborated with an immune checkpoint antagonist for combination immunotherapy","volume":"8","author":"Hu","year":"2019","journal-title":"Adv. Healthcare Mater."},{"issue":"30","key":"10.1016\/j.bbrc.2024.151215_bib23","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.1073\/pnas.2005794117","article-title":"Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer","volume":"117","author":"Callmann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24017510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24017510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:40:36Z","timestamp":1736300436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X24017510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":23,"alternative-id":["S0006291X24017510"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.151215","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.151215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151215"}}